Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Declines By 58.7%

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 31,500 shares, a drop of 58.7% from the December 15th total of 76,200 shares. Based on an average daily trading volume, of 787,700 shares, the short-interest ratio is currently 0.0 days.

Astellas Pharma Trading Up 0.1 %

Shares of ALPMY opened at $9.48 on Tuesday. The stock’s 50-day moving average price is $10.17 and its 200 day moving average price is $11.02. The company has a quick ratio of 0.72, a current ratio of 0.90 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $17.16 billion, a price-to-earnings ratio of 45.15 and a beta of 0.34. Astellas Pharma has a 12-month low of $9.15 and a 12-month high of $13.14.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.13 earnings per share (EPS) for the quarter. The business had revenue of $3.11 billion for the quarter. Astellas Pharma had a return on equity of 10.33% and a net margin of 3.26%. As a group, research analysts predict that Astellas Pharma will post 0.61 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.